Shigatoxin 1 抗体
适用: Shigella dysenteriae
WB, IA, InhA
宿主: 小鼠
Monoclonal
13C4
unconjugated
(2 references)-
- 抗原
- Shigatoxin 1
- 适用
- Shigella dysenteriae
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- 非结合性
- 应用范围
- Western Blotting (WB), Immunoassay (IA), Inhibition Assay (InhA)
- 过滤
- 0.2 μm filtered
- 克隆位点
- 13C4
-
-
- 应用备注
- For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amounts of toxin to be inactivated.
- 限制
- 仅限研究用
-
- 缓冲液
- PBS, containing 0.1 % bovine serum albumin.
- 储存条件
- 4 °C
- 储存方法
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
- 有效期
- 12 months
-
-
: "Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2." in: Vaccine, Vol. 24, Issue 19, pp. 4122-9, (2006) (PubMed).
: "Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli." in: Infection and immunity, Vol. 50, Issue 3, pp. 695-700, (1986) (PubMed).
-
: "Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2." in: Vaccine, Vol. 24, Issue 19, pp. 4122-9, (2006) (PubMed).
-
- 抗原
- Shigatoxin 1
- 背景
- The monoclonal antibody 13C4 recognizes the 1B subunit of Shiga-like toxin 1. Shiga-like toxins (SLTs), are also called Verotoxins. Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11 and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share >99 % deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60 % deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.
-
You are here:
